Literature DB >> 16612664

Multiple evidence for an early age pro-oxidant state in Down Syndrome patients.

Federico V Pallardó1, Paolo Degan, Marco d'Ischia, Frank J Kelly, Adriana Zatterale, Rita Calzone, Giuseppe Castello, Rafael Fernandez-Delgado, Christina Dunster, Ana Lloret, Paola Manini, Maria Antonietta Pisanti, Emilia Vuttariello, Giovanni Pagano.   

Abstract

Oxidative stress has been associated with Down syndrome (DS) and with its major phenotypic features, such as early ageing. In order to evaluate an in vivo pro-oxidant state, the following analytes were measured in a group of DS patients aged 2 months to 57 years: (a) leukocyte 8-hydroxy-2'-deoxyguanosine (8-OHdG); (b) blood glutathione; (c) plasma levels of: glyoxal (Glx) and methylglyoxal (MGlx); some antioxidants (uric acid, UA, ascorbic acid, AA and Vitamin E), and xanthine oxidase (XO) activity. A significant 1.5-fold increase in 8-OHdG levels was observed in 28 DS patients vs. 63 controls, with a sharper increase in DS patients aged up to 30 years. The GSSG:GSH x 100 ratio was significantly higher in young DS patients (< 15 years), in contrast to DS patients aged >or=15 years that showed a significant decrease in the GSSG:GSH x 100 ratio ratio vs. controls of the respective age groups. Plasma Glx levels were significantly higher in young DS patients, whereas no significant difference was detected in DS patients aged >or=15 years. Unlike Glx, the plasma levels of MGlx were found to be significantly lower in DS patients vs. controls. A significant increase was observed in plasma levels of UA in DS patients that could be related to an increased plasma XO activity in DS patients. The plasma concentrations of AA were also increased in young (< 15 years) DS patients, but not in older patients vs. controls in the same age range. The levels of Vitamin E in DS patients did not differ from the values determined in control donors. The evidence for a multiple pro-oxidant state in young DS patients supports the role of oxidative stress in DS phenotype, with relevant distinctions according to patients' ages.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16612664     DOI: 10.1007/s10522-006-9002-5

Source DB:  PubMed          Journal:  Biogerontology        ISSN: 1389-5729            Impact factor:   4.277


  22 in total

1.  An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach.

Authors:  Giovanna Cenini; Ada Fiorini; Rukhsana Sultana; Marzia Perluigi; Jian Cai; Jon B Klein; Elizabeth Head; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2014-08-20       Impact factor: 7.376

2.  A noradrenergic lesion exacerbates neurodegeneration in a Down syndrome mouse model.

Authors:  Jason Lockrow; Heather Boger; Greg Gerhardt; Gary Aston-Jones; David Bachman; Ann-Charlotte Granholm
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 3.  4-Hydroxy-2-nonenal, a reactive product of lipid peroxidation, and neurodegenerative diseases: a toxic combination illuminated by redox proteomics studies.

Authors:  Marzia Perluigi; Raffaella Coccia; D Allan Butterfield
Journal:  Antioxid Redox Signal       Date:  2012-02-15       Impact factor: 8.401

Review 4.  HNE-modified proteins in Down syndrome: Involvement in development of Alzheimer disease neuropathology.

Authors:  Eugenio Barone; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Free Radic Biol Med       Date:  2016-11-10       Impact factor: 7.376

5.  Systemic oxidative stress, as measured by urinary allantoin and F(2)-isoprostanes, is not increased in Down syndrome.

Authors:  Adviye A Tolun; Peter M Scarbrough; Haoyue Zhang; Jane-Ann McKillop; Frances Wang; Priya S Kishnani; David S Millington; Sarah P Young; Dora Il'yasova
Journal:  Ann Epidemiol       Date:  2012-10-11       Impact factor: 3.797

6.  Down's syndrome and myocardial reperfusion injury.

Authors:  Susheel Kumar; Richard Jonas
Journal:  J Saudi Heart Assoc       Date:  2010-09-09

7.  Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome.

Authors:  Diane C Cabelof; Hiral V Patel; Qing Chen; Holly van Remmen; Larry H Matherly; Yubin Ge; Jeffrey W Taub
Journal:  Blood       Date:  2009-07-24       Impact factor: 22.113

8.  Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model.

Authors:  Jason Lockrow; Annamalai Prakasam; Peng Huang; Heather Bimonte-Nelson; Kumar Sambamurti; Ann-Charlotte Granholm
Journal:  Exp Neurol       Date:  2008-12-10       Impact factor: 5.330

9.  Clinical course and outcome for critically ill children with Down syndrome: a retrospective cohort study.

Authors:  Shane M Tibby; Andrew Durward; Chong Tien Goh; Kentigern Thorburn; Kevin Morris; Mike Broadhead; Mark J Peters
Journal:  Intensive Care Med       Date:  2012-05-15       Impact factor: 17.440

Review 10.  Oxidative stress and mitochondrial dysfunction in Alzheimer's disease.

Authors:  Xinglong Wang; Wenzhang Wang; Li Li; George Perry; Hyoung-gon Lee; Xiongwei Zhu
Journal:  Biochim Biophys Acta       Date:  2013-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.